– Steven
Closter brings more than 30 years of commercial experience
in the biopharmaceutical industry to Syndax –
– Company on track for two potential
first- and best-in-class product launches in 2024 –
WALTHAM, Mass., March 18, 2024 /PRNewswire/ -- Syndax
Pharmaceuticals (Nasdaq: SNDX), a clinical stage biopharmaceutical
company developing an innovative pipeline of cancer therapies,
today announced the appointment of Steven Closter as
Chief Commercial Officer, effective immediately. Mr. Closter will
lead the Company's commercial strategy and operations, including
marketing, sales, and market access, succeeding Steve Sabus, who is departing for personal
reasons.
"Steven Closter is an
accomplished leader with a proven track record of building
commercial teams, leading successful product launches and
delivering growth across a broad range of therapeutic areas," said
Michael A. Metzger, Chief Executive
Officer. "He has the right experience and capabilities to lead our
growing and talented commercial organization as we work toward a
successful transition to a fully integrated commercial business. We
are thrilled to welcome him to the team and look forward to his
contributions."
Mr. Closter brings to Syndax over 30 years of commercial
experience, which included the oversight of over a dozen product
launches and indication expansions. Prior to joining Syndax, he
served in various roles at Sunovion Pharmaceuticals, which was
consolidated into Sumitomo Pharma America in 2023, ultimately
serving as Vice President, Brand
Strategy and Launch Excellence. At Sunovion, he was
responsible for global pre-commercialization, launch, marketing,
sales, and market access strategies for products across neurology,
psychiatry, and primary care therapeutics. Before Sumitomo, Mr.
Closter spent nearly 20 years in senior marketing and commercial
roles at Forest Laboratories, then Allergan, most recently serving
as Vice President, Marketing, where he held responsibility for
marketing products covering oncology, hospital-based
anti-infectives, CNS, cardiovascular and other therapeutic areas.
He holds a Bachelor of Science in Business from Cornell University and a Master of Business
Administration from the NYU Stern School of Business.
"I have dedicated my career to strategically delivering novel
medicines to patients facing a wide range of serious diseases and
conditions," said Mr. Closter. "Syndax is at a pivotal moment, with
the expected delivery of two first- and best-in-class therapies
this year to people living with cancer. I look forward to leading
the continued build-out of Syndax's commercial organization and
strategies, and to helping position the Company for success in the
anticipated launch of revumenib and axatilimab."
Mr. Metzger added: "We thank Steve
Sabus for his contributions to Syndax and for his assistance
in seamlessly transitioning the role to Steven Closter. His guidance and insights helped
lay a solid foundation for our commercial organization that has
positioned us to be fully ready to launch. We are grateful to him
for his leadership and wish him the best."
About Syndax
Syndax Pharmaceuticals is a
clinical stage biopharmaceutical company developing an innovative
pipeline of cancer therapies. Highlights of the Company's pipeline
include revumenib, a highly selective inhibitor of the menin–KMT2A
binding interaction, and axatilimab, a monoclonal antibody that
blocks the colony stimulating factor 1 (CSF-1) receptor. For more
information, please visit www.syndax.com or follow the
Company on X (formerly Twitter) and LinkedIn.
Forward-Looking Statements
This press release contains
forward-looking statements within the meaning of the Private
Securities Litigation Reform Act of 1995. Words such as
"anticipate," "believe," "could," "estimate," "expects," "intend,"
"may," "plan," "potential," "predict," "project," "should," "will,"
"would" or the negative or plural of those terms, and similar
expressions (as well as other words or expressions referencing
future events, conditions or circumstances) are intended to
identify forward-looking statements. These forward-looking
statements are based on Syndax's expectations and assumptions as of
the date of this press release. Each of these forward-looking
statements involves risks and uncertainties. Actual results may
differ materially from these forward-looking statements.
Forward-looking statements contained in this press release include,
but are not limited to, statements about the progress, timing,
clinical development and scope of clinical trials, the reporting of
clinical data for Syndax's product candidates, and the potential
use of its product candidates to treat various cancer indications
and fibrotic diseases. Many factors may cause differences between
current expectations and actual results, including: unexpected
safety or efficacy data observed during preclinical or clinical
trials; clinical trial site activation or enrollment rates that are
lower than expected; changes in expected or existing competition;
changes in the regulatory environment; failure of Syndax's
collaborators to support or advance collaborations or product
candidates; and unexpected litigation or other disputes. Other
factors that may cause Syndax's actual results to differ from those
expressed or implied in the forward-looking statements in this
press release are discussed in Syndax's filings with the U.S.
Securities and Exchange Commission, including the "Risk Factors"
sections contained therein. Except as required by law, Syndax
assumes no obligation to update any forward-looking statements
contained herein to reflect any change in expectations, even as new
information becomes available.
Syndax Contact
Sharon
Klahre
Syndax Pharmaceuticals, Inc.
sklahre@syndax.com
Tel 781.684.9827
SNDX-G
View original
content:https://www.prnewswire.com/news-releases/syndax-announces-appointment-of-steven-closter-as-chief-commercial-officer-302091049.html
SOURCE Syndax Pharmaceuticals